Folic Acid Rapid Test

Name: Folic Acid (FA) Rapid Test
SKU: DTS831L
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

COA

SDS

Datasheet

Sample

Serum, whole blood

Intended Use

Folic Acid Rapid Test is a rapid, one step test for the qualitative detection of folic acid in human serum sample.

Storage

Store at 4-30°C, DO NOT FREEZE or use beyond the expiration date. The shelf life is 12 months.

Detection Limit

The detection limit of folic acid with this test is about 1 ng/mL (ppb).

General Description

Folic acid (FA) is an important B vitamin made up of 2-amino-4-hydroxyl-6-methylpterin, para-amino benzoic acid, and glutamic acid. FA exists in a large variety of foods including green leafy vegetables, fruits, meat products, beans, fermented dairy products, and cereals, but the content of FA in natural foods is not high, which dissatisfies with demands of the human body. FA deficiency has been associated with a number of health disorders such as mental confusion, diarrhea, irritability, behavior disorder, and headache or nerve damage. Besides, insufficient intake of FA can lead to neural tube defects in developing embryos, elevated plasma homocysteine, different types of cancer, Alzheimer, etc. The daily recommended intake (DRI) as approved in European Union (EU) is 400 μg day−1 for adults; higher intake (600 μg day−1) is recommended for women before and during pregnancy. FA has special importance for pregnant women and infants, and FA supplementation is particularly important in those edible foods. Therefore, monitoring FA content is necessary to guarantee the quality of functional foods.

Citations

Have you cited DTS831L in a publication? Let us know and earn a reward for your research.

Product Name	Cat. No.	Applications	Host Species	Datasheet	Price	Add to Basket

Product Name	Cat. No.	Applications	Host Species	Datasheet	Price	Add to Basket

Datasheet

Certificate of Analysis

Safety Data Sheet

Customer Reviews

Write a review

SARS CoV-2 aggravates cellular metabolism mediated complications inCOVID-19 infection

DERMATOLOGIC THERAPY

Authors: Singh, Yogendra; Gupta, Gaurav; Kazmi, Imran; Al-Abbasi, Fahad A.; Negi, Poonam; Chellappan, Dinesh Kumar; Dua, Kamal

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the primary causative organism in corona virus disease-19 (COVID-19) infections, is a novel member of the human coronavirus family which was first identified in Wuhan, China, towards the end of 2019. This letter reveals new vital missing links in our current understanding of the mechanisms that lead to cell death triggered by ferroptotic stress in COVID-19 infection. It further reveal the importance of homocysteine mediated trans-sulfuration pathway in COVID-19 infection. Hence, Vitamin B6, folic acid, and Vitamin B12 should be incorporated in the treatment regimen for SARS CoV-2 infections to suppress complications, as the virus mediates altered host cell metabolism.

Enzymatic synthesis of PEGylated lactide-diester-diol copolyesters for highly efficient targeted anticancer drug delivery

MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS

Authors: Su, Meifei; Xie, Jianhua; Zeng, Qiang; Shu, Man; Liu, Jie; Jiang, Zhaozhong

Abstract

PEGylated lactide-diester-diol copolymers were successfully synthesized via lipase-catalyzed copolymerization, the resultant amphiphilic PEG-poly(L-lactate-co-hexamethylene-co-adipate) (PEG-PLLHA) and PEG-poly(D,L-lactate-co-hexamethylene-co-adipate) (PEG-PDLLHA) block copolymers readily undergo self-assembly processes to form nanosized micelles in aqueous medium, which are stable under physiological conditions in the presence of serum proteins. By conjugating folic acid (FA) to enzymatic synthesized poly(hexamethylene adipate-co-hexamethylene 2,3-epoxy succinate), we could formulate FA-bearing PEG-polyester micelles for docetaxel (DTX) targeting delivery. FA-PEG-PLLHA and FA-PEG-PDLLHA micelles possess efficient cell-targeting capability toward FA receptor-positive cancer cells (e.g., CT-26), which significantly enhances their cellular uptake rates and efficacy of drug-loaded formulations toward such cells. During in vivo anticancer treatments, the FA-bearing micelles are highly capable of targeting and accumulating preferentially in tumor tissues by both active cell-targeting mechanism and passive targeting via the EPR effect. All these desirable properties enable the FA-bearing micelles to deliver DTX with 97% tumor-inhibiting efficiency through systemic delivery, which is favorable in comparison to the values of various DTX nanoparticle formulations reported in literature. Importantly, biosafety assays reveal that all DTX-loaded micelles are biocompatible and safe for in vivo antitumor treatment applications. Thus, FA-PEG-PLLHA and FA-PEG-PDLLHA micelles represent new types of promising anticancer drug nanocarriers for targeted chemotherapy.